Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
16 1월 2019 - 10:30PM
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the
“Company”), a clinical-stage biopharmaceutical company, today
announced the appointment of Linda Grais, M.D., J.D. to its board
of directors.
Dr. Grais brings a diverse and important set of experience and
expertise to Zosano. After graduation from Yale Medical School and
residency at UCSF, she was an assistant professor at UCSF in
internal medicine, received her J.D. from Stanford Law School where
she was an editor of Stanford Law and Policy Review before joining
Wilson Sonsini Goodrich & Rosati as an associate representing
Life Science companies. Dr. Grais then founded Structural GenomiX
Inc, which was sold to Eli Lilly & Co. in 2008 and became a
partner at InterWest Partners, a venture capital firm, investing in
biotechnology and medical device companies. Dr. Grais became the
President and CEO of Ocera Therapeutics, Inc. in 2012 and
successfully led Ocera through the acquisition by Mallinckrodt in
2017. She currently serves on the Board of Directors of Arca
Biopharma (NASDAQ: ABIO) and PRA Health Sciences (NASDAQ:
PRAH).
“Linda brings a unique combination of expertise to Zosano
Pharma,” commented John Walker Chairman and CEO. "Her experience in
clinical medicine, drug development, corporate transactions and
managing complex strategic issues will serve us well as we continue
to development our drug delivery technology and expand our clinical
portfolio.”
“I am very pleased to join the Board of Zosano Pharma at this
exciting time for the company. With the projected filing of the
company’s first NDA in the fourth quarter, expansion of the
clinical portfolio in new therapeutic areas and the continued
development of Zosano’s drug delivery platform for biological
agents, there is much to accomplish, and much that I hope to
contribute,” said Dr. Grais.
About Qtrypta (M207)Qtrypta is Zosano’s lead
program and is a proprietary formulation of zolmitriptan delivered
utilizing its proprietary ADAM technology. Zosano's ADAM technology
consists of titanium microneedles coated with drug, and in the case
of Qtrypta, its formulation of zolmitriptan. The drug-coated
microneedles penetrate into the epidermis and dermis, where the
investigational drug is dissolved and enters into the bloodstream.
In February 2017, the Company announced statistically significant
results from the ZOTRIP pivotal study, in which the 3.8mg dose of
Qtrypta met both co-primary endpoints, achieving pain freedom and
most bothersome symptom freedom at 2 hours. In November 2017, the
Company announced the initiation of its long-term safety study
evaluating Qtrypta and expects to file an NDA for Qtrypta in the
fourth quarter of 2019.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the expected timing of an NDA for Qtrypta and other future events
and expectations. Readers are urged to consider statements that
include the words "may," "will," "would," "could," "should,"
"might," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," "approximately" or the negative of
those words or other comparable words to be uncertain and
forward-looking. These statements are subject to risks and
uncertainties that are difficult to predict and actual outcomes may
differ materially. These include, without limitation, risks
and uncertainties associated with the process of discovering,
developing and commercializing products that are safe and effective
for use as human therapeutics, risks inherent in the effort to
build a business around such products and other risks and
uncertainties described under the heading "Risk Factors" in the
Company's most recent quarterly report on Form 10-Q. Although
Zosano believes that the expectations reflected in these
forward-looking statements are reasonable, we cannot in any way
guarantee that the future results, level of activity, performance
or events and circumstances reflected in forward-looking statements
will be achieved or occur. All forward-looking statements are based
on information currently available to Zosano and Zosano assumes no
obligation to update any such forward-looking statements.
Zosano Contact:Greg KitchenerChief Financial
Officer 510-745-1200
Media Contact:Sara ZelkovicLifeSci Public
Relationssara@lifescipublicrelations.com646-876-4933
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024